Received Jan 7, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Shingrix + late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 69-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received first dose on 20-OCT-2022). On 17-AUG-2025, the patient received the 2nd dose of Shingrix. On 17-AUG-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Shingrix + late second dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 05-JAN-2026 The reporter reported that patient received the first dose for Shingrix on 20-OCT-2022 and then a second dose on 17-AUG-2025. The reporter mentioned that the patient was indicated to restart the series because the second dose was given late, no third dose had been administered at the time of the call. The batch number was not provided upon follow- up with the reporter.